Cleared Traditional

K863209 - US PLUS-PAK SURGICAL SYSTEM

K863209 is an FDA 510(k) clearance for US PLUS-PAK SURGICAL SYSTEM, manufactured by Ipax, Inc.. The device is a Class 2 Ophthalmic device with product code HQC cleared through the Traditional 510(k) pathway after a 19-day FDA review.

K863209 · Ipax, Inc. · Ophthalmic device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Sep 1986
Decision
19d
Days
Class 2
Risk

K863209 is an FDA 510(k) clearance for the US PLUS-PAK(R) SURGICAL SYSTEM. Classified as Unit, Phacofragmentation (product code HQC), Class II - Special Controls.

Submitted by Ipax, Inc. (Englewood, US). The FDA issued a Cleared decision on September 8, 1986 after a review of 19 days - a notably fast clearance cycle.

This device falls under the Ophthalmic FDA review panel, regulated under 21 CFR 886.4670 - the FDA ophthalmic device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Ipax, Inc. devices

FDA 510(k) Submission Details - K863209

510(k) Number K863209 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 20, 1986
Decision Date September 08, 1986
Days to Decision 19 days
Submission Type Traditional
Review Panel Ophthalmic (OP)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
91d faster than avg
Panel avg: 110d · This submission: 19d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

HQC Device Classification - Class 2, Special Controls

Product Code HQC Unit, Phacofragmentation
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 886.4670
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Ophthalmic devices follow this clearance model.

Regulatory Peers - HQC Unit, Phacofragmentation

All 123
Devices cleared under the same product code (HQC) and FDA review panel - the closest regulatory comparables to K863209.
IN-LINE OPHTHALMIC IRRIGATING SOLUTION FILTERS
K871854 · CooperVision, Inc. · Jul 1987
SITE PHACOEMULSIFICATION SYSTEM/OPHTHALMIC USE
K871485 · Site Microsurgical Systems, Inc. · Jun 1987
SITE PHACOEMULSIFICATION SYST/OPHTHALMIC USE (MOD)
K864301 · Site Microsurgical Systems, Inc. · Dec 1986
SITE PHACO DISPOSABLE CASSETTE
K861060 · Site Microsurgical Systems, Inc. · May 1986
COOPERVISION ACAP POWER DRIVE ULTRASONIC ANTERIOR
K854375 · CooperVision, Inc. · Dec 1985
COOPER VISION SYSTEM VI U/S MODULE
K853070 · CooperVision, Inc. · Aug 1985